Compounds > 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol
Page last updated: 2024-08-26

4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol and Cancer of the Urinary Tract

4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol has been researched along with Cancer of the Urinary Tract in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chung, CJ; Hsueh, YM; Lee, HL; Lin, P; Pu, YS; Shiue, HS; Su, CT; Yang, HY1
Chung, CJ; Hsueh, YM; Huang, CY; Lee, HL; Lin, P; Pu, YS; Su, CT; Wu, CC1

Other Studies

2 other study(ies) available for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol and Cancer of the Urinary Tract

ArticleYear
Low ratio of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol-glucuronides (NNAL-Gluc)/free NNAL increases urothelial carcinoma risk.
    The Science of the total environment, 2011, Apr-01, Volume: 409, Issue:9

    Topics: Biomarkers; Carcinoma; Case-Control Studies; Female; Glucuronides; Humans; Male; Middle Aged; Nitrosamines; Pyridines; Risk Factors; Smoking; Urologic Neoplasms

2011
Joint effect of arsenic methylation profile and NNK metabolites on urothelial carcinoma.
    The Journal of urology, 2012, Volume: 188, Issue:5

    Topics: Arsenic; Carcinoma, Transitional Cell; Case-Control Studies; Humans; Methylation; Nitrosamines; Pyridines; Risk; Smoking; Urologic Neoplasms

2012